SynCardia Portable Freedom Driver: A Single-Center Experience With 11 Patients

Nilay R. Shah, Dawn E. Jaroszewski, Awais Ashfaq, Lucas A. Schroedl, Linda L. Staley, Octavio E. Pajaro, Vigneshwar Kasirajan, Francisco A. Arabia

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

OBJECTIVE: The portable Freedom Drive (SynCardia Inc, Tucson, AZ USA) for total artificial heart (TAH-t) support was approved for an investigational device exemption study in March 2010. We review our center's experience with the portable driver.

METHODS: A retrospective review was conducted of patients who underwent TAH-t implantation and transfer to portable driver from September 2008 to June 2012, with follow-up through December 2012.

RESULTS: A total of 30 patients underwent TAH-t implantation during this time period, with 11 patients successfully transferred to the Freedom Driver. Transfer to Freedom Driver after TAH-t implant was a median of 46 days (range, 225-86 days). Ninety-one percent (10) of 11 patients transferred to Freedom Driver were bridged to transplantation. One patient died on support. Five (45.5%) of 11 patients were discharged home and 5 (45.5%) remained in-patient on the portable driver before transplantation. Four patients (80%) successfully discharged home required at least 1 hospital readmission (range, 1-5 admissions per patient). Six patients (55%) transferred to the portable driver required a return to a main driver console. Two patients were temporarily maintained on the main driver then returned to the Freedom Driver for bridge to transplantation.

CONCLUSIONS: Patients with TAH-t can be considered for transfer to the portable Freedom Driver while awaiting transplantation. Issues that complicated this patient population included inadequate social support, hemodynamic instability, and concurrent morbidities. The potential benefits of the portable driver are currently undergoing assessment. These may include increased mobility and improved quality of life, opportunity for discharge home, and decreased overall medical costs.

Original languageEnglish (US)
Pages (from-to)188-194
Number of pages7
JournalInnovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Volume10
Issue number3
DOIs
StatePublished - May 1 2015

Fingerprint

Artificial Heart
Transplantation
Patient Admission
Social Support
Prostheses and Implants
Hemodynamics
Quality of Life
Morbidity
Costs and Cost Analysis
Equipment and Supplies
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shah, N. R., Jaroszewski, D. E., Ashfaq, A., Schroedl, L. A., Staley, L. L., Pajaro, O. E., ... Arabia, F. A. (2015). SynCardia Portable Freedom Driver: A Single-Center Experience With 11 Patients. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 10(3), 188-194. https://doi.org/10.1097/IMI.0000000000000161

SynCardia Portable Freedom Driver : A Single-Center Experience With 11 Patients. / Shah, Nilay R.; Jaroszewski, Dawn E.; Ashfaq, Awais; Schroedl, Lucas A.; Staley, Linda L.; Pajaro, Octavio E.; Kasirajan, Vigneshwar; Arabia, Francisco A.

In: Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, Vol. 10, No. 3, 01.05.2015, p. 188-194.

Research output: Contribution to journalArticle

Shah, NR, Jaroszewski, DE, Ashfaq, A, Schroedl, LA, Staley, LL, Pajaro, OE, Kasirajan, V & Arabia, FA 2015, 'SynCardia Portable Freedom Driver: A Single-Center Experience With 11 Patients', Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, vol. 10, no. 3, pp. 188-194. https://doi.org/10.1097/IMI.0000000000000161
Shah, Nilay R. ; Jaroszewski, Dawn E. ; Ashfaq, Awais ; Schroedl, Lucas A. ; Staley, Linda L. ; Pajaro, Octavio E. ; Kasirajan, Vigneshwar ; Arabia, Francisco A. / SynCardia Portable Freedom Driver : A Single-Center Experience With 11 Patients. In: Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. 2015 ; Vol. 10, No. 3. pp. 188-194.
@article{2b44c9f417d34cfb978ef24f4013ea14,
title = "SynCardia Portable Freedom Driver: A Single-Center Experience With 11 Patients",
abstract = "OBJECTIVE: The portable Freedom Drive (SynCardia Inc, Tucson, AZ USA) for total artificial heart (TAH-t) support was approved for an investigational device exemption study in March 2010. We review our center's experience with the portable driver.METHODS: A retrospective review was conducted of patients who underwent TAH-t implantation and transfer to portable driver from September 2008 to June 2012, with follow-up through December 2012.RESULTS: A total of 30 patients underwent TAH-t implantation during this time period, with 11 patients successfully transferred to the Freedom Driver. Transfer to Freedom Driver after TAH-t implant was a median of 46 days (range, 225-86 days). Ninety-one percent (10) of 11 patients transferred to Freedom Driver were bridged to transplantation. One patient died on support. Five (45.5{\%}) of 11 patients were discharged home and 5 (45.5{\%}) remained in-patient on the portable driver before transplantation. Four patients (80{\%}) successfully discharged home required at least 1 hospital readmission (range, 1-5 admissions per patient). Six patients (55{\%}) transferred to the portable driver required a return to a main driver console. Two patients were temporarily maintained on the main driver then returned to the Freedom Driver for bridge to transplantation.CONCLUSIONS: Patients with TAH-t can be considered for transfer to the portable Freedom Driver while awaiting transplantation. Issues that complicated this patient population included inadequate social support, hemodynamic instability, and concurrent morbidities. The potential benefits of the portable driver are currently undergoing assessment. These may include increased mobility and improved quality of life, opportunity for discharge home, and decreased overall medical costs.",
author = "Shah, {Nilay R.} and Jaroszewski, {Dawn E.} and Awais Ashfaq and Schroedl, {Lucas A.} and Staley, {Linda L.} and Pajaro, {Octavio E.} and Vigneshwar Kasirajan and Arabia, {Francisco A.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1097/IMI.0000000000000161",
language = "English (US)",
volume = "10",
pages = "188--194",
journal = "Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery",
issn = "1556-9845",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - SynCardia Portable Freedom Driver

T2 - A Single-Center Experience With 11 Patients

AU - Shah, Nilay R.

AU - Jaroszewski, Dawn E.

AU - Ashfaq, Awais

AU - Schroedl, Lucas A.

AU - Staley, Linda L.

AU - Pajaro, Octavio E.

AU - Kasirajan, Vigneshwar

AU - Arabia, Francisco A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - OBJECTIVE: The portable Freedom Drive (SynCardia Inc, Tucson, AZ USA) for total artificial heart (TAH-t) support was approved for an investigational device exemption study in March 2010. We review our center's experience with the portable driver.METHODS: A retrospective review was conducted of patients who underwent TAH-t implantation and transfer to portable driver from September 2008 to June 2012, with follow-up through December 2012.RESULTS: A total of 30 patients underwent TAH-t implantation during this time period, with 11 patients successfully transferred to the Freedom Driver. Transfer to Freedom Driver after TAH-t implant was a median of 46 days (range, 225-86 days). Ninety-one percent (10) of 11 patients transferred to Freedom Driver were bridged to transplantation. One patient died on support. Five (45.5%) of 11 patients were discharged home and 5 (45.5%) remained in-patient on the portable driver before transplantation. Four patients (80%) successfully discharged home required at least 1 hospital readmission (range, 1-5 admissions per patient). Six patients (55%) transferred to the portable driver required a return to a main driver console. Two patients were temporarily maintained on the main driver then returned to the Freedom Driver for bridge to transplantation.CONCLUSIONS: Patients with TAH-t can be considered for transfer to the portable Freedom Driver while awaiting transplantation. Issues that complicated this patient population included inadequate social support, hemodynamic instability, and concurrent morbidities. The potential benefits of the portable driver are currently undergoing assessment. These may include increased mobility and improved quality of life, opportunity for discharge home, and decreased overall medical costs.

AB - OBJECTIVE: The portable Freedom Drive (SynCardia Inc, Tucson, AZ USA) for total artificial heart (TAH-t) support was approved for an investigational device exemption study in March 2010. We review our center's experience with the portable driver.METHODS: A retrospective review was conducted of patients who underwent TAH-t implantation and transfer to portable driver from September 2008 to June 2012, with follow-up through December 2012.RESULTS: A total of 30 patients underwent TAH-t implantation during this time period, with 11 patients successfully transferred to the Freedom Driver. Transfer to Freedom Driver after TAH-t implant was a median of 46 days (range, 225-86 days). Ninety-one percent (10) of 11 patients transferred to Freedom Driver were bridged to transplantation. One patient died on support. Five (45.5%) of 11 patients were discharged home and 5 (45.5%) remained in-patient on the portable driver before transplantation. Four patients (80%) successfully discharged home required at least 1 hospital readmission (range, 1-5 admissions per patient). Six patients (55%) transferred to the portable driver required a return to a main driver console. Two patients were temporarily maintained on the main driver then returned to the Freedom Driver for bridge to transplantation.CONCLUSIONS: Patients with TAH-t can be considered for transfer to the portable Freedom Driver while awaiting transplantation. Issues that complicated this patient population included inadequate social support, hemodynamic instability, and concurrent morbidities. The potential benefits of the portable driver are currently undergoing assessment. These may include increased mobility and improved quality of life, opportunity for discharge home, and decreased overall medical costs.

UR - http://www.scopus.com/inward/record.url?scp=84973421531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973421531&partnerID=8YFLogxK

U2 - 10.1097/IMI.0000000000000161

DO - 10.1097/IMI.0000000000000161

M3 - Article

C2 - 26181585

AN - SCOPUS:84973421531

VL - 10

SP - 188

EP - 194

JO - Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery

JF - Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery

SN - 1556-9845

IS - 3

ER -